The Oncology Institute Inc. (TOI)
NASDAQ (CM) NASDAQ (CM) Primary 
The Oncology Institute, Inc. (TOI) Reports Q2 Loss, Misses Revenue Estimates
The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.19 per share a year ago.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
The Oncology Institute, Inc. (TOI) Q1 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Jack Slevin - Jefferies Operator Good afternoon and welcome to The Oncology Institute's First Quarter 2024 Earnings Conference Call. Today's call is being recorded.
